Evidence map›Paper›PMID 39146503›Full record

ArticleHuman molecular genetics2024

Alzheimer's disease risk gene CD2AP is a dose-sensitive determinant of synaptic structure and plasticity.

Matea Pavešković, Ruth B De-Paula, Shamsideen A Ojelade, Evelyne K Tantry, Mikhail Y Kochukov, Suyang Bao, Surabi Veeraragavan, Alexandra R Garza, Snigdha Srivastava, Si-Yuan Song and 9 more

Abstract read
In one paragraph

Article in Human molecular genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Matea PaveškovićDepartment of Neuroscience, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States.
Ruth B De-PaulaJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, 1250 Moursund Street, Houston, TX 77030, United States.
Shamsideen A OjeladeJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, 1250 Moursund Street, Houston, TX 77030, United States.
Evelyne K TantryJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, 1250 Moursund Street, Houston, TX 77030, United States.ORCID 0000-0002-1782-0692
Mikhail Y KochukovJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, 1250 Moursund Street, Houston, TX 77030, United States.
Suyang BaoJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, 1250 Moursund Street, Houston, TX 77030, United States.
Surabi VeeraragavanJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, 1250 Moursund Street, Houston, TX 77030, United States.
Alexandra R GarzaJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, 1250 Moursund Street, Houston, TX 77030, United States.
Snigdha SrivastavaJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, 1250 Moursund Street, Houston, TX 77030, United States.
Si-Yuan SongDepartment of Neuroscience, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States.
Masashi FujitaCenter for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th Street, New York, NY, United States.
Duc M DuongDepartments of Biochemistry and Neurology, Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA 30322, United States.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, 600 S. Paulina Street, Chicago, IL 60612, United States.
Philip L De JagerCenter for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th Street, New York, NY, United States.
Nicholas T SeyfriedDepartments of Biochemistry and Neurology, Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA 30322, United States.
Mary E DickinsonDepartment of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States.
Jason D HeaneyDepartment of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States.
Benjamin R ArenkielDepartment of Neuroscience, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States.
Joshua M ShulmanDepartment of Neuroscience, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States.ORCID 0000-0002-1835-1971

Funding

UNDERSTANDING FXTAS AMONG MALES WITH THE FMR1 PREMUTATIONP30HD024064 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI THALLER, CHRISTINA · 1988 to 2013
$29.4M
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targetsU01AG061356 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2018 to 2022
$13.7M
Preclinical and Clincial OutcomesP50HD103555 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI MIRJANA MALETIC-SAVATIC · 2020 to 2026
$9.9M
Supplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF BiomarkersU01AG061357 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I, SEYFRIED, NICHOLAS THOMAS · 2018 to 2022
$9.1M
Alzheimer variants: Propagation of shared functional changes across cellular networksU01AG072572 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DE JAGER, PHILIP L, ST GEORGE-HYSLOP, PETER HENRY · 2021 to 2025
$8.5M
Functional Genomic Dissection of Alzheimer's Disease in Humans and Drosophila ModelsU01AG072439 · NIA · BAYLOR COLLEGE OF MEDICINE · PI BELLEN, HUGO J, BOTAS, JUAN · 2021 to 2025
$8.4M
Deconstructing and modeling the single cell architecture of the Alzheimer brainRF1AG057473 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2017 to 2018
$4.0M
Functional Validation of the CD2AP Susceptibility Network in Alzheimer's DiseaseR01AG050631 · NIA · BAYLOR COLLEGE OF MEDICINE · PI SHULMAN, JOSHUA M · 2016 to 2020
$2.5M
Alzheimer's Association fellowship AARFD-16-442630Burroughs Wellcome Fund BWF-1017399Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNIA NIH HHS R01 AG050631NIA NIH HHS RF1 AG057473NIA NIH HHS U01 AG061356NIA NIH HHS U01 AG061357NIA NIH HHS U01 AG072439NIA NIH HHS U01 AG072572NICHD NIH HHS P30 HD024064NICHD NIH HHS P50 HD103555NIH HHS R01AG050631Wellcome Trust 1017399
6 · The paper itself

Abstract

CD2-Associated protein (CD2AP) is a candidate susceptibility gene for Alzheimer's disease, but its role in the mammalian central nervous system remains largely unknown. We show that CD2AP protein is broadly expressed in the adult mouse brain, including within cortical and hippocampal neurons, where it is detected at pre-synaptic terminals. Deletion of Cd2ap altered dendritic branching and spine density, and impaired ubiquitin-proteasome system activity. Moreover, in mice harboring either one or two copies of a germline Cd2ap null allele, we noted increased paired-pulse facilitation at hippocampal Schaffer-collateral synapses, consistent with a haploinsufficient requirement for pre-synaptic release. Whereas conditional Cd2ap knockout in the brain revealed no gross behavioral deficits in either 3.5- or 12-month-old mice, Cd2ap heterozygous mice demonstrated subtle impairments in discrimination learning using a touchscreen task. Based on unbiased proteomics, partial or complete loss of Cd2ap triggered perturbation of proteins with roles in protein folding, lipid metabolism, proteostasis, and synaptic function. Overall, our results reveal conserved, dose-sensitive requirements for CD2AP in the maintenance of neuronal structure and function, including synaptic homeostasis and plasticity, and inform our understanding of possible cell-type specific mechanisms in Alzheimer's Disease.

Indexed as

Adaptor Proteins, Signal TransducingAlzheimer DiseaseNeuronal PlasticitySynapsesAnimalsBrainCytoskeletal ProteinsDisease Models, AnimalGenetic Predisposition to DiseaseHippocampusHumansMaleMiceMice, KnockoutNeuronsAdaptor Proteins, Signal TransducingCD2-associated proteinCytoskeletal ProteinsAlzheimer’s diseaseapolipoproteinsCD2APendocytosishaploinsufficiencylipid metabolismplasticityproteomicsproteostasissynapse

Identifiers

PMID39146503
PMCPMC11458016

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.